After delaying its review, the FDA has rejected Aldeyra Therapeutics’ experimental dry eye disease treatment for the third time. | After delaying its review, the FDA has rejected Aldeyra Therapeutics’ ...

In its complete response letter, the FDA said Aldeyra had failed to demonstrate reproxalap’s efficacy in adequate and ...

Previously, the Company had received CRLs in November 2023 and April 2025 due to insufficient evidence in addressing the ...

The US Food and Drug Administration (FDA) has issued a Complete Response Letter to Aldeyra Therapeutics for its New Drug Application of reproxalap for the treatment of dry eye dis ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced ...

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) said it has received a Complete Response Letter from the U.S. Food and Drug Administration rejecting its New Drug Application for reproxalap, a proposed ...

Aldeyra Therapeutics Inc. ALDX shares are tumbling on Tuesday following the U.S. Food and Drug Administration (FDA) update.

Aldeyra Therapeutics shares fell 70% after the FDA issued a third rejection for its dry-eye drug, citing a lack of evidence ...

Shares of Aldeyra Therapeutics fell sharply in premarket trading Tuesday said the U.S. health regulator rejected its dry-eye drug, saying that the company failed to show the treatment works. Shares ...

FDA rejection was attributed to a lack of substantial evidence of efficacy, including inconsistencies that undermined confidence in reproducibility across investigations. Reproxalap targets reactive ...

A Houston-area woman claims a postgame fireworks show left her with lasting vision loss.

Pets may not be able to speak, but they often show clear signs when something isn’t right. From digestive troubles to itchy skin, many common health issues can make them uncomfortable. The good news ...